.svg)
The global oral solid dosage formulation market is projected to grow from approximately US$623.4 billion two years ago, to US$949.8 billion by 2034, reflecting a CAGR of around 4.3%. While tablets and capsules continue to account for substantial market volume, faster growth is emerging across specialised formats designed around administration, adherence and differentiated drug delivery.
The continued strength of oral dosage forms is not surprising. They combine established manufacturing infrastructure with scalability. It is also easy to self-administration and applicability across acute and chronic therapies. However, the next phase of the market is moving beyond conventional tablet production. Chronic therapies, patent expiries, formulation advances are reshaping where pharmaceutical companies invest. Greater attention to patient-centric drug delivery is also influencing how existing molecules are differentiated.
Several forces are changing the commercial requirements for oral products rather than simply increasing their overall volume.
Chronic therapy demand: Cardiovascular, metabolic, respiratory, and CNS conditions often require medication over extended periods. This increases the value of dosage forms that can simplify administration, reduce dosing frequency, or otherwise support long-term use.
Patient expectations: Swallowability, dosing frequency, taste, and ease of administration increasingly influence formulation decisions. This is expanding development interest beyond standard tablets towards ODTs, films, mini-tablets and modified-release products.
Patent expiries: As small-molecule products lose exclusivity, companies have opportunities to develop generic oral formulations that stand apart from the originator. Differentiate can ome through release profile, dosage form, strength, fixed-dose combinations or improved administration.
Patient-focused development: Dosage-form design increasingly considers the requirements of populations such as paediatric, geriatric, and dysphagic patients rather than treating the formulation simply as a vehicle for the API.
Chronic disease growth → Long-term oral therapy demand
Patient convenience → Easier administration and adherence-focused formats
Patent expiries → Differentiated and complex generics
Formulation advances → New delivery and release possibilities
CDMO capabilities → Access to specialised development and scale-up expertise
Conventional immediate-release tablets will remain important, but innovation is increasingly concentrated in formats that solve a defined formulation or administration problem.
Orally disintegrating tablets (ODTs) offer water-free administration and can be valuable when swallowing conventional tablets is difficult. Oral thin films (OTFs) provide a thin, portable platform with opportunities for rapid disintegration, taste masking, and differentiated delivery. The OTF market alone was estimated at approximately US$2.3 billion in 2025 and is projected to reach US$6.5 billion by 2035.
Sublingual formulations are also attracting interest where the API and therapeutic objective are suitable for absorption through the oral mucosa. Meanwhile, modified-release tablets and multiparticulate systems provide other routes to address dosing frequency, flexible dosing, and administration requirements.
Adoption varies by therapeutic need. CNS and neurological therapies, pain management, and antiemetics can benefit from simplified or rapid administration. Cardiovascular and metabolic products, meanwhile, provide more opportunities for modified-release technologies and fixed-dose combinations.
These developments form part of a broader move towards designing the dosage form around both the molecule and the intended user; an approach explored further in Oral Dosage Forms and Patient-Centric Design: An Overview.
For pharmaceutical companies, differentiation is increasingly possible at the formulation level. An established API can potentially be developed into a new product proposition through modified release, an alternative administration format, a fixed-dose combination or technologies addressing solubility, taste and other formulation constraints.
This is particularly relevant to generic oral formulations, where competing solely on the molecule leaves limited room for differentiation. Formulation design can support lifecycle strategies while addressing specific patient or therapeutic requirements.
At the same time, these products can require capabilities beyond conventional tableting. Spray drying, hot-melt extrusion, specialised polymers, taste-masking systems and advanced oral delivery platforms introduce additional development and scale-up requirements.
This is increasing the relevance of CDMO oral formulations capabilities. Pharmaceutical companies can access specialised formulation technologies, analytical expertise and commercial manufacturing infrastructure without establishing every capability internally. The supplied market data reflects this importance, with solid-dose products accounting for a substantial share of finished-dose contract manufacturing activity.
Three developments are likely to influence where oral formulation portfolios move next.
Multifunctional formulation technologies: Co-processed excipients, advanced polymers, permeation enhancers and improved taste-masking technologies are giving formulators more options to solve multiple product requirements within one dosage form.
More personalised dosing: Mini-tablets, multiparticulates, scored products and other dose-flexible formats can support greater variation in strength and dosing requirements. Fixed-dose combinations can address a different challenge by consolidating multiple therapies into a simpler regimen.
Lifecycle differentiation: As portfolios mature and patents expire, reformulating an existing molecule around administration, release or patient requirements can provide an additional route for product development.
The key question isn’t whether to replace conventional tablets. It’s which oral dosage form best fits the molecule, the target population, the therapeutic objective and the commercial strategy.
The oral dosage forms market is expanding in two directions: continued demand for scalable conventional products and growing investment in differentiated formats designed around specific formulation and patient requirements.
For pharmaceutical companies, future opportunities will increasingly involve combining robust manufacturing with patient-centric drug delivery, whether through ODTs, oral thin films, sublingual formulations, modified-release products or differentiated generics.
ZIM Laboratories Limited is a therapy-agnostic and innovative drug delivery solution provider focusing on enhancing patient convenience and treatment adherence to drug intake. We offer a range of technology-based drug delivery solutions and non-infringing proprietary manufacturing processes to develop, manufacture, and supply innovative and differentiated generic pharmaceutical products to our customers globally. At ZIM Labs, we provide our customers with a comprehensive range of oral solid value-added, differentiated generic products in semi-finished and finished formulations. These include granules, pellets (sustained, modified, and extended-release), taste-masked powders, suspensions, tablets, capsules, and Oral Thin Films (OTF).
